Genomic Classification and Prognosis in Acute Myeloid LeukemiaElli Papaemmanuil, Peter J. Campbell, Iñigo Martincorena et al.|New England Journal of Medicine|2016Cited by 4.4k
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaJennifer R. Brown, Mazyar Shadman, Barbara Eichhorst et al.|New England Journal of Medicine|2022Cited by 453
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple MyelomaVânia Hungria, María-Victoria Mateos, Paweł Robak et al.|New England Journal of Medicine|2024Cited by 162
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III TrialPeter Hillmen, Wojciech Jurczak, Barbara Eichhorst et al.|Journal of Clinical Oncology|2022Cited by 93
Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)Jennifer R. Brown, Mazyar Shadman, Barbara Eichhorst et al.|Blood|2023Cited by 24